Novel Approaches to Pelvic Mass Risk Assessment and Management: Case Reviews

ACOG District II Annual Meeting - New York, October 18, 2019

ACOG District XII Annual Meeting - Orlando, August 12, 2022

  • Clinical Perspectives 
  • Full Video
  • Presentation Slides

Richard G. Moore, MD, FACS, FACOG

  • Professor University of Rochester
  • Chief, Division of Gynecologic Oncology University of Rochester Medical Center
  • Director, Targeted Therapeutics Laboratory Chair, Gynecology Service Line Wilmot Cancer Institute

Kevin Holcomb, MD, FACOG

  • Vice-Chairman of Gynecology
  • Director of Gynecologic Oncology
  • Director of Gynecologic Minimally Invasive Surgery
  • Weill Cornell Medicine

Clinical Perspectives

Why consider other biomarkers in addition to CA125?
Are multi-marker algorithms recommended for pelvic mass referrals to a gynecologic oncologist?
When to refer patients with adnexal mass to a gynecologic oncologist?
What improved performance does HE4 offer with CA125?
Why a multi-marker algorithm was developed to assess a pelvic mass?
What data support ROMA?
How does ROMA compare to clinical assessment?
Benefits for patients and OB-Gynecologists